



Improving Treatment Pathways for Patients with Persistent Lower Urinary Tract Symptoms

A resource for clinicians who have patients experiencing lower urinary tract symptoms (LUTS) despite negative standard urine culture (SUC), as well as patients who do not respond to treatment based on positive SUC.

ADVISORS

Michael Hsieh, MD, Ph.D.

Medical Advisor

Professor, School of Medicine and Health Sciences, The George Washington University
Washington, District of Columbia, USA

Krystal Thomas-White, Ph.D.

Scientific Research Advisor

Postdoctoral Researcher, Department of Microbiology and Immunology, Stanford University
Stanford, California, USA

Katherine Finlay, Ph.D., C.Psychol

Clinical Research Advisor

Lecturer, Health Psychology, University of Reading
Reading, England, UK

Lindsey Roberts, Ph.D.

Patient Research Advisor

Lecturer, Health Psychology, University of Buckingham
Buckingham, England, UK

Jessica Price

Patient Involvement Advisor, Author

Melissa Kramer

Patient Involvement Advisor, Editor





“The literature on urinary microbiome testing is expanding, and can be useful to review as we treat patients with either recurrent culture-positive UTIs or what I refer to as ‘culture-negative UTIs’. I’ve seen patients who have been labeled as having IC, however, microbiome analysis clearly shows pathogens in their urine. When we’ve treated these pathogens, their symptoms have resolved.

“I think some patients with the diagnosis of interstitial cystitis have an occult UTI with difficult to culture organisms. By utilizing more accurate testing methods, we are able to identify pathogens in many cases, and develop appropriate treatment. Even as a physician who has conducted microbiome research for a number of years, I was initially skeptical of urine microbiome testing as a means to diagnose UTI. However, based upon patient and clinical experience, microbiome testing appears to not only be accurate in the right setting, but also may predict imminent UTI in some patients.”


— Michael Hsieh, MD, PhD



TABLE OF CONTENTS

For digital copies, select a page number to jump to that section.

INTRODUCTION	<u>1</u>
KEYWORDS & DEFINITIONS	<u>2</u>
THE BLADDER IS NOT STERILE	<u>3</u>
Current Research into the Bladder Microbiome	
False-Negative Standard Urine Culture	
OVERCOMING THE LIMITATIONS OF STANDARD URINE CULTURE	<u>5</u>
Enhanced Detection Methods:	<u>6</u>
• Expanded Quantitative Urine Culture (EQUC)	
• Fresh Urine Microscopy	
• Polymerase Chain Reaction (PCR)	
• Next-Generation Sequencing (NGS)	
Table 2: Comparison of urinary diagnostic methods	<u>7</u>
CONTAMINATION vs. POLYMICROBIAL INFECTION	<u>8</u>
A MORE ACCURATE APPROACH TO DETECTING RESISTANCE	<u>9</u>
Antibiotic Susceptibility Testing	
Resistance Genes	
SYMPTOMS OF A COMPLEX UTI	<u>11</u>
When a Difficult to Diagnose UTI Should be Considered	
THE ROLE OF BIOFILM IN CULTURE-NEGATIVE UTI	<u>13</u>
How Biofilm Contributes to Approximately 80% of Recurrent Infections and Influences Antibiotic Resistance	
Increasing Antibiotic Resistance and Horizontal Gene Transfer	
ENHANCED DIAGNOSTIC DIRECTORY	<u>16</u>
REFERENCES	<u>18-19</u>



INTRODUCTION

The purpose of this document is to provide an overview of the limitations of standard urine culture (SUC) for patients with lower urinary tract symptoms (LUTS) and persistent urinary tract infection (UTI) that responds poorly to standard treatment. Here, clinicians are provided with additional diagnostic resources for improving clinical outcomes in patients with persistent UTI and LUTS.

This document highlights the limitations of current gold standard diagnostics and presents methods available to address these limitations. The peer-reviewed articles referenced below indicate that a shift in UTI diagnostics improves treatment and quality of life (QOL) outcomes for patients experiencing persistent or difficult to diagnose urinary tract symptoms.

While SUC may be negative for some patients experiencing LUTS, when additional diagnostics are utilized, uropathogenic organisms may be identified in these patients and greater treatment success achieved. The term 'culture-negative UTI' is applied in these circumstances. Therefore, a culture-negative UTI should be considered as part of a differential diagnosis, and enhanced testing methods should be utilized in an effort to improve diagnostics and treatment decisions for patients with lower urinary tract symptoms.

FIGURE 1: Microbe Detection Rate in Symptomatic Patients^{1,11-13,21}





FIGURE 2: Urinary Symptom Improvement Following Treatment Based upon Diagnostic Method^{11,14}





KEYWORDS AND DEFINITIONS

- ◆ **Biofilm:** Bacterial communities encased in a polysaccharide matrix capable of adhering to and inside surfaces and tissues; contribute to diagnostic and treatment difficulties
- ◆ **Culture-negative urinary tract infection:** UTI is present and contributing to lower urinary tract symptoms despite a negative standard urine culture
- ◆ **Dysbiosis:** A decrease of microbial diversity in which a reduction of beneficial bacteria or an increase of pathogenic bacteria exist in a microbiome
- ◆ **Expanded Quantitative Urine Culture (EQUC):** A more sensitive culture-dependent diagnostic tool which adjusts for the limitations of standard urine culture
- ◆ **Horizontal Gene Transfer:** The transfer of resistance behaviors between microbes
- ◆ **Intracellular bacterial communities (IBC):** Bacterial communities that exist within urothelial cells in a biofilm-like state
- ◆ **Next-Generation Sequencing (NGS):** An enhanced DNA-based microbial detection method that can examine all microbes present in a sample
- ◆ **Polymerase Chain Reaction (PCR):** An enhanced DNA-based microbial detection method that amplifies microbial DNA using 16s and 18s rRNA to identify microbes from a panel
- ◆ **Polymicrobial infection:** An infection that consists of multiple pathogens
- ◆ **Shotgun metagenomic sequencing:** An advanced NGS diagnostic method in which the entire genome of an organism is sequenced
- ◆ **Urobiome:** The microbiome of the urinary tract

THE BLADDER IS NOT STERILE

Identifying the urinary microbiome and addressing standard urine culture limitations

“Our previous study showed that bacterial genomes can be identified using 16S rRNA sequencing in urine specimens of both symptomatic and asymptomatic patients who are culture negative according to standard urine culture protocols... Our current study demonstrates that urine contains communities of living bacteria that comprise a resident female urine microbiota.”

— Hilt et al. (2013), **Urine Is Not Sterile: Use of Enhanced Urine Culture Techniques To Detect Resident Bacterial Flora in the Adult Female Bladder**

Current research into the bladder microbiome:


- Bacterial communities have been observed in 80% of samples obtained by transurethral catheter of female participants, with up to 92% of the samples being reported as ‘no growth’ using SUC.¹ A dysbiosis of this healthy urinary microbiome (the urobiome) is correlated with the development of symptoms and urinary disorders.¹⁻³
- Participants with urinary symptoms demonstrated a more diverse urobiome with larger quantities of bacteria than asymptomatic controls. The frequency of bacterial detection was between 81% and 86% for symptomatic cohorts compared to only 57% in the control cohort.^{1,2,4,5}
- When compared with asymptomatic controls, patients experiencing urgency incontinence had statistically significant differences in their urobiome, with lower levels of *Lactobacillus* and higher levels of *Gardnerella*.^{6,7,8}

TABLE 1: Documented Limitations of Standard Urine Culture

Inability to detect slow-growing microorganisms
Inability to grow non-aerobic organisms
Poor detection of gram-positive organisms
Poor detection of organisms under 10 ³ CFU/ml
Threshold developed for pyelonephritis applied to acute cystitis
Distinctions of unique organism thresholds not accounted for
Polymicrobial infection reported as contamination
Poor detection of organisms contained within biofilm
Poor detection of organisms contained within urothelial cells

Fallacies of standard urine culture (SUC) and urinary dipsticks:

- Urinary dipsticks are often utilized as the first method of UTI diagnostics, however, their detection of leukocyte-esterase has been shown to have low sensitivity (0.76) and specificity (0.46).⁹ While urinary dipsticks can provide evidence of infection, they cannot accurately determine that no infection is present and are, therefore, an unreliable method for ruling out a UTI in a symptomatic patient.¹⁰
- The standard urine culture has been determined to be up to 90% inaccurate when tested against more sensitive testing methods, such as an Expanded Quantitative Urine Culture (EQUC) or 16s rRNA sequencing. Cultures reported as “no growth” or “insufficient growth” may be missing a significant portion of infections.^{2,6,7,11-14}
- SUC has been shown to be ineffective at detecting Gram-positive microorganisms. Additionally, SUC fails to detect microorganisms in the following categories: slow-growing, anaerobic, colonies present under the threshold of 10^3 CFU/ml, and microbes encased within biofilm or within urothelial cells, also known as intracellular bacterial communities (IBCs).^{6,11,12}
- Polymicrobial infections are often reported as “mixed growth” or “contamination.” However, current SUC methods result in an overdiagnosis of *E. coli* infection and misdiagnosis of up to 65% of other infections that contain multiple species.^{11,14,15}
- Existing SUC procedures do not account for IBCs contained within exfoliated urothelial cells. Up to 10^5 CFU of bacteria can be present in a single cell. However, without proper homogenization to release the microbes, current SUC methods may detect and report these bacteria as only a single colony.^{6,15}
- The issue of culture-negative infection is not isolated to the urinary tract and SUC. Studies completed by Kuzmar et al. and Bernard et al. demonstrate that 29-68% of patients diagnosed with sepsis receive a negative blood culture, and empiric antimicrobial treatment is initiated.¹⁶⁻¹⁸
- In patients with culture-negative sepsis, advanced microbial diagnostics result in a 20% increased detection rate and a reduction in inadequate treatment.¹⁸
- More sensitive testing methods, reviewed in the following section, may more effectively diagnose an infection or an imbalance within the urobiome of symptomatic patients.





OVERCOMING THE LIMITATIONS OF STANDARD URINE CULTURE

Testing methods that more accurately
represent the state of the urobiome

“Enhanced [expanded] quantitative urine culture (EQUC) detects live microorganisms in the vast majority of urine specimens reported as “no growth” by the standard urine culture protocol...The streamlined EQUC protocol improves detection of uropathogens that are likely relevant for symptomatic women, giving clinicians the opportunity to receive additional information not currently reported using standard urine culture techniques.”

— Price et al. (2016), *The Clinical Urine Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms*

A quick-reference table summarizing testing methods [can be viewed below](#).

Standard urine culture (SUC) compared to alternative diagnostic methods:

The diagnostic methods reviewed in this section have been shown to more accurately detect dysbiosis of the urobiome, with links to improved patient outcomes.

- Expanded Quantitative Urine Culture (EQUC) detected known uropathogenic bacteria in 84% of urine samples compared to only 33% using SUC.¹²
- DNA and RNA based next-generation sequencing (NGS) detected bacteria in 100% of samples compared to 29% with SUC. Due to the high sensitivity rate of NGS, treatment recommendations should be carefully considered, as not all microbes present may be contributing to LUTS.^{1,12,14}
- Patients treated according to either fresh urine microscopy results or more sensitive diagnostic methods reported increased symptom improvement when compared to patients treated according to SUC results only.^{10,14}
 - On a 21 point scale, patients who were treated according to SUC antibiotic sensitivity testing (AST) reported an average symptom severity decrease of 3.7 points.¹⁴
 - Patients treated according to NGS results reported an average symptom severity decrease of 7.9 points.¹⁴

Enhanced detection methods:

- **Expanded Quantitative Urine Culture (EQUC):** Because SUC misses between 67% and 90% of bacteria and is unable to detect certain microorganisms, a more sensitive culture-dependent approach has been established. EQUC adjusts the following conditions to improve detection of slow-growing, anaerobic, and Gram-positive bacteria: volume of urine, media used, atmospheric conditions, and incubation period.¹²
- **Fresh Urine Microscopy:** This diagnostic method examines a urine sample under a microscope to assess the pyuria count. Due to cell integrity being compromised during centrifugation, a fresh, unspun urine sample is necessary. Epithelial cells may also be present, as the bladder lining sheds within six hours of exposure to bacterial strains, such as *E. coli*, in an effort to clear the attached bacteria.¹⁹ Microscopy sidesteps the limitations of SUC as it does not rely on plating conditions, but rather considers the patient's immune response as an indicator of infection. When urine samples of 624 patients experiencing LUTS were examined with both microscopy and SUC, 100% of the samples revealed high pyuria count, whereas only 16% had a positive SUC.¹⁰
- **Polymerase Chain Reaction (PCR):** PCR amplifies small sections of microbial DNA in order to analyze the genome. Microbes can be identified based on a pre-selected panel, which varies by the lab. An enhanced approach dependent on PCR is 16s sequencing (metataxonomics). While metataxonomic provides more detailed analysis, limitations in differentiating bacterial strains still exist. When compared to EQUC, similar urobiomes have been observed. This similarity indicates that organisms identified via PCR testing are likely living.^{6,20,21}
- **Next-Generation Sequencing (NGS):** NGS is a non-targeted testing method that uses either 16s rRNA or shotgun sequencing (metagenomic) to detect microbes from a database of up to 50,000 organisms, dependent upon the lab. Millions of DNA strands are independently sequenced, minimizing the need for DNA amplification and providing a detailed look into the urobiome.^{22,23} Treatment recommendations according to resistance genes are available through some NGS testing facilities.

For a list of available diagnostic tests utilizing these methods, see the [Enhanced Diagnostics Directory](#)
on page 16



TABLE 2: Comparison of urinary microbe testing methods

Comparison of UTI Diagnostic Methods

	SUC	EQUC	PCR (16s)	NGS*	Fresh Unspun Urine Microscopy
Polymicrobial detection	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Detects indicators of infection
Detects anaerobic microbes	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Detects indicators of infection
Detects microbes within biofilm	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Detects indicators of infection
Threshold requirement for diagnosis	$\geq 10^3$	Unique to the microbe	N/A	N/A	N/A
Microbe detection rate in symptomatic patients	30-43% ^{10,11}	92% ¹	56% ²⁰	100% ¹²	N/A
Polymicrobial detection rate in symptomatic patients	5.2-6.6% ^{11,20}	18-42% ¹⁰	28.5-33% ^{12,20}	77% ¹³	N/A
Antibiotic recommendations method	Standard Antibiotic Susceptibility Testing (AST)	Standard Antibiotic Susceptibility Testing (AST) - <i>where available</i>	Typically resistance gene detection only Pooled-Antibiotic Susceptibility Testing (P-AST) - <i>where available</i>	Resistance gene detection only	N/A
Advantages	Detection of <i>E. coli</i>	Improved detection of: <ul style="list-style-type: none"> Polymicrobial infection Slow-growing organisms Anaerobic organisms Microbes within biofilm Microbes attached to epithelial cells Threshold unique to microbe Greater response to treatment	Improved detection of: <ul style="list-style-type: none"> Polymicrobial infection Slow-growing organisms Anaerobic organisms Microbes within biofilm Microbes attached to epithelial cells Higher sensitivity rate Rapid identification Genetic resistance detection	Improved detection of: <ul style="list-style-type: none"> Polymicrobial infection Slow-growing organisms Anaerobic organisms Microbes within biofilm Microbes attached to epithelial cells Database of up to 50,000 organisms Distribution of organisms reported Greater response to treatment	Improved detection of: <ul style="list-style-type: none"> White blood cells Epithelial cells Host immune response
Limitations	Biased toward <i>E. coli</i> detection Unlikely to detect: <ul style="list-style-type: none"> Slow-growing organisms Anaerobic organisms Organisms under 10^3 Gram-positive organisms Polymicrobial infection 	Not easily accessible	Detection limited to specific panel of organisms; varies by lab May not detect dominant species	Interpretation by physician necessary	Interpretation by physician necessary Detection of pathogenic organisms limited
Turnaround Time	2-7 days	2-4 days	6-24 hours	3-5 days	Immediate

* Please note that current research around NGS has been completed by MicroGen Diagnostics

Download the table in [full size here](#)



SYMPTOMS OF A PERSISTENT UTI

Overlapping symptoms of urinary conditions present
a need to consider culture-negative UTI

“Lower urinary tract symptoms (LUTS) may be associated with chronic urinary tract infection (UTI) undetected by routine diagnostic tests. Antimicrobial therapy might confer benefit for these patients. Over 10 years, we treated patients with chronic LUTS. Pyuria was adopted as the principal biomarker of infection. Urinary leucocyte counts were recorded from microscopy of fresh midstream urine (MSU) samples. Antibiotics were prescribed and the prescription adjusted to achieve a measurable clinical response and a reduction in pyuria.

“This large case series demonstrates that patients with chronic LUTS and pyuria experience symptom regression and a reduction in urinary tract inflammation associated with antimicrobial therapy. Disease regression was achieved with a low frequency of AEs. These results provide preliminary data to inform a future randomized controlled trial (RCT).”

— Swamy et al. (2018), **Recalcitrant chronic bladder pain and recurrent cystitis but negative urinalysis: What should we do?**

- The symptom presentation of urinary conditions such as overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS), and persistent UTI often overlap. Given the established limitations of standard urine culture (SUC), in the presence of any of the below symptoms, a negative culture should not be considered conclusive, and a culture-negative or persistent UTI should be considered.^{6,10}
- Study participants with urinary urgency incontinence (UUI) have more urobiome diversity than non-UUI controls.^{4,7} When lower urinary tract symptoms are present, consideration of a patient's unique microbiota and microscopy examination can have a positive impact on treatment outcomes.^{4,10}
- A prospective, double-blind study performed by Warren et al. demonstrated that 48% of participants diagnosed with IC who underwent antibiotic treatment for 18 weeks reported either a reduction in urgency and pain, or an overall improvement in symptoms, compared to 24% of those in the placebo group. While further studies are needed, this outcome suggests that patients with urinary symptom complexes may have an undiagnosed UTI.^{6,27}

Undiagnosed Persistent UTI Should be Considered in Patients Experiencing the Following Symptoms:

TABLE 3: Symptom Overlap Between UTI, OAB, and IC/PBS

KEY:	Persistent UTI ●	IC / PBS ●	OAB ●
Urgency	●	●	●
Frequency	●	●	●
Incontinence	●	●	●
Nocturia	●	●	●
Double voiding	●	●	●
Dysuria	●	●	
Hematuria	●	●	
Bladder filling & voiding pain	●	●	
Pain unchanged by voiding	●	●	
Loin pain	●	●	
Pain radiating to genitals & legs	●	●	
Urethral pain	●	●	
Pelvic pain	●	●	
Vaginal pain	●	●	
Pain during sex	●	●	
Reduced stream	●	●	
Straining to void	●	●	
Post-micturition dribbling	●	●	
Foul smelling urine	●		





THE ROLE OF BIOFILM IN PERSISTENT AND CULTURE-NEGATIVE UTI

How intracellular bacterial communities and biofilms contribute to treatment difficulty

“Occult and recurrent urinary tract infection may be due to both invasion of the bladder wall by uropathogenic *Escherichia coli* and the formation of biofilm-like intracellular bacterial communities.”

— Scott et al. (2015), Intracellular Bacterial Communities: A Potential Etiology for Chronic Lower Urinary Tract Symptoms

“We discovered that the intracellular bacteria matured into biofilms, creating pod-like bulges on the bladder surface. Pods contained bacteria encased in a polysaccharide-rich matrix surrounded by a protective shell of uroplakin. Within the biofilm, bacterial structures interacted extensively with the surrounding matrix, and biofilm associated factors had regional variation in expression. The discovery of intracellular biofilm-like pods explains how bladder infections can persist in the face of robust host defenses.”

— Anderson et al. (2003), Intracellular Bacterial Biofilm-Like Pods in Urinary Tract Infections

TABLE 4: Characteristics of Biofilm that Contribute to Antibiotic Resistance

Antibiotic-inactivating enzymes

Horizontal Gene Transfer between organisms

Barriers against:


- Host immune cells
- Antibodies
- Antimicrobials

How biofilm contributes to approximately 80% of recurrent infections and influences antibiotic resistance²⁸:

- Rate of recurrence:** After the initial onset of an acute UTI, the risk of future recurrence increases. 19-24% of women will have a recurrent UTI within 6 months of their first infection, and for those patients who have a history of UTIs, 70% will have a recurrence within one year.^{10,29} Multiple factors previously discussed, such as standard urine culture (SUC) bias and sensitivity report limitations, contribute to increased recurrence rates. However, the presence of biofilm plays a significant role.

- **Bacterial biofilms:** Biofilms are bacterial communities encased in a polysaccharide matrix capable of adhering to and inside surfaces and tissues, expressing antibiotic resistance genes, and greatly influencing the development of chronic infections.²⁸ *E. coli* specifically is a high biofilm-producing bacterium, responsible for contributing to chronic and recurrent infection, with 62.5% of *E. coli* infections shown to produce biofilm.^{6,30,31}
- **Intracellular bacterial communities (IBCs):** IBCs occur when bacteria invade urothelial cells and can be found at varying depths of the bladder epithelia. IBCs take on biofilm-like qualities and, like biofilms, are difficult to detect using standard urine culture (SUC) and are extremely difficult to treat.³⁰ As much as 10⁵ CFU of bacteria are capable of existing in one single shed urothelial cell.⁶ However, because SUC methods do not encourage a release of bacteria within the cell, the community is reported as only a single colony. See Figure 4-A below.
- **Adherence to urothelium:** Biofilms and IBCs in the bladder adhere to and inside the urothelium. At times dormant, bacteria within these communities are difficult to detect and effectively treat, however, they continue to colonize and modify gene expression. Biofilm and IBC pods eventually break open, releasing planktonic bacteria and reinfecting the host. Without intervention, the process continues.^{6,30}
- **Prevalence:** When compared with asymptomatic controls, 75% of patients with lower urinary tract symptoms (LUTS) had evidence of IBCs compared to 17% found in controls, indicating the potential role of biofilm in urinary symptoms.⁶ As explained by Scott et al., "IBCs may have a role not only in the etiology of recurrent UTI but also of chronic LUTS experienced by some women who are given the diagnosis of OAB or IC/BPS."⁶
- **Other biofilm-associated infections:** Biofilms and IBCs are recognized as being associated with other tissue infections, such as dental infections, respiratory tract infections, endocarditis, prostatitis, and more.²⁸


FIGURE 4: Intracellular bacterial community



Intracellular bacterial communities attached to the bladder wall of a mouse. (A to C) The biofilm-like pod is magnified to show bacterial communities.³⁰

Increasing antibiotic resistance and horizontal gene transfer:

- Compared to planktonic bacteria, microbes encased in biofilm are 10-1,000 times more resistant to antibiotics,²⁸ with 64% of biofilm-forming *E. coli* infections being multi-drug resistant (MDR) compared to 36% for non-biofilm forming *E. coli* infections.³²
- Increased resistance is due to the following: Biofilms and IBCs provide microbes with a barrier against host immune cells and antibodies and antimicrobials, in addition to harboring antibiotic-inactivating enzymes. The prominent differentiation between conventional antibiotic resistance and biofilm antibiotic resistance is the altered environment that takes place within the biofilm due to their multicellular nature.²⁸
- The transfer of resistance behaviors between microbes, known as horizontal gene transfer (HGT), can occur as a result of increased inflammation in the host as well as in response to antibiotics that promote bacterial lysis. Through the process of HGT, bacterial resistance increases.^{24,33}
- The prevalence and defense behaviors of biofilms and IBCs make them a necessary consideration for patients with culture-negative, recurrent, persistent, and multi-drug resistant UTI, as early intervention may disrupt the multicellular structure and aid in achieving better clinical outcomes.^{6,30}



ENHANCED DIAGNOSTICS DIRECTORY

About the Directory

This diagnostic directory includes molecular testing laboratories that meet the following criteria:

1. Services offered go beyond the standard urine culture
2. The company has demonstrated a commitment to improving patient outcomes
3. The company has demonstrated a commitment to supporting the patient advocacy work of Live UTI Free

US

EmeritusDX

UTIDX™ is a urine-based test designed to identify pathogens commonly associated with recurrent or persistent urinary tract infections while determining the best treatment options for the patient.

PCR technology is paired with traditional microbiology to ensure rapid results while providing personalized therapy options for patients. EmeritusDX, your trusted partner in diagnosing and treating UTIs.

emeritusdx.com





REFERENCES

1. Hilt EE, Mckinley K, Pearce MM, et al. Urine Is Not Sterile: Use of Enhanced Urine Culture Techniques To Detect Resident Bacterial Flora in the Adult Female Bladder. *Journal of Clinical Microbiology*. 2013;52(3):871-876. doi: [10.1128/jcm.02876-13](https://doi.org/10.1128/jcm.02876-13)
2. Wolfe A, Toh E, Shibata N et al. Evidence of Uncultivated Bacteria in the Adult Female Bladder. *J Clin Microbiol*. 2012;50(4):1376-1383. doi: [10.1128/jcm.05852-11](https://doi.org/10.1128/jcm.05852-11)
3. Thomas-White K, Brady M, Wolfe AJ, Mueller ER. The Bladder Is Not Sterile: History and Current Discoveries on the Urinary Microbiome. *Current Bladder Dysfunction Reports*. 2016;11(1):18-24. doi: [10.1007/s11884-016-0345-8](https://doi.org/10.1007/s11884-016-0345-8)
4. Price T, Lin H, Gao X et al. Bladder bacterial diversity differs in continent and incontinent women: a cross-sectional study. *Am J Obstet Gynecol*. 2020;223(5):729.e1-729.e10. doi: [10.1016/j.ajog.2020.04.033](https://doi.org/10.1016/j.ajog.2020.04.033)
5. Thomas-White, K., Forster, S., Kumar, N., Van Kuiken, M., Putonti, C., Stares, M., Hilt, E., Price, T., Wolfe, A. and Lawley, T., 2018. Culturing of female bladder bacteria reveals an interconnected urogenital microbiota. *Nature Communications*, 9(1). doi: [10.1038/s41467-018-03968-5](https://doi.org/10.1038/s41467-018-03968-5)
6. Scott V, Haake D, Churchill B, Justice S, Kim J. Intracellular Bacterial Communities: A Potential Etiology for Chronic Lower Urinary Tract Symptoms. *Urology*. 2015;86(3):425-431. doi: [10.1016/j.urology.2015.04.002](https://doi.org/10.1016/j.urology.2015.04.002)
7. Thomas-White K, Hilt E, Fok C et al. Incontinence medication response relates to the female urinary microbiota. *Int Urogynecol J*. 2015;27(5):723-733. doi: [10.1007/s00192-015-2847-x](https://doi.org/10.1007/s00192-015-2847-x)
8. Karstens L, Asquith M, Davin S et al. Does the Urinary Microbiome Play a Role in Urgency Urinary Incontinence and Its Severity? *Front Cell Infect Microbiol*. 2016;6. doi: [10.3389/fcimb.2016.00078](https://doi.org/10.3389/fcimb.2016.00078)
9. Devillé, W., Yzermans, J., van Duijn, N., Bezemer, P., van der Windt, D. and Bouter, L., 2004. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. *BMC Urology*, 4(1). doi: [10.1186%2F1471-2490-4-4](https://doi.org/10.1186%2F1471-2490-4-4)
10. Swamy S, Barcella W, Iorio MD, et al. Recalcitrant chronic bladder pain and recurrent cystitis but negative urinalysis: What should we do? *International Urogynecology Journal*. 2018;29(7):1035-1043. doi: [10.1007/s00192-018-3569-7](https://doi.org/10.1007/s00192-018-3569-7)
11. Price TK, Hilt EE, Dune TJ, Mueller ER, Wolfe AJ, Brubaker L. Urine trouble: should we think differently about UTI? *International Urogynecology Journal*. 2017;29(2):205-210. doi: [10.1007/s00192-017-3528-8](https://doi.org/10.1007/s00192-017-3528-8)
12. Price T, Dune T, Hilt E et al. The Clinical Urine Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms. *J Clin Microbiol*. 2016;54(5):1216-1222. doi: [10.1128/jcm.00044-16](https://doi.org/10.1128/jcm.00044-16)
14. McDonald M, Kameh D, Johnson ME, Johansen TEB, Albala D, Mouraviev V. A Head-to-Head Comparative Phase II Study of Standard Urine Culture and Sensitivity Versus DNA Next-generation Sequencing Testing for Urinary Tract Infections. *Rev Urol*. 2017;19(4):213-220. doi: [10.3909/riu0780](https://doi.org/10.3909/riu0780)
15. Khasriya R, Sathiananthamoorthy S, Ismail S et al. Spectrum of Bacterial Colonization Associated with Urothelial Cells from Patients with Chronic Lower Urinary Tract Symptoms. *J Clin Microbiol*. 2013;51(7):2054-2062. doi: [10.1128/jcm.03314-12](https://doi.org/10.1128/jcm.03314-12)

16. Kumar A, Ellis P, Arabi Y et al. Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock. *Chest*. 2009;136(5):1237-1248. doi: [10.1378/chest.09-0087](https://doi.org/10.1378/chest.09-0087)
17. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. *Critical Care Medicine*. 2001;29(11):2051-2059. doi: [10.1097/00003246-200111000-00003](https://doi.org/10.1097/00003246-200111000-00003)
18. Nannan Panday RS, Lammers EMJ, Alam N, Nanayakkara PWB. An overview of positive cultures and clinical outcomes in septic patients: a sub-analysis of the Prehospital Antibiotics Against Sepsis (PHANTASi) trial. *Crit Care*. 2019;23(1). doi: [10.1186/s13054-019-2431-8](https://doi.org/10.1186/s13054-019-2431-8)
19. Mulvey M. Induction and Evasion of Host Defenses by Type 1-Piliated Uropathogenic Escherichia coli. *Science* (1979). 1998;282(5393):1494-1497. doi: [10.1126/science.282.5393.1494](https://doi.org/10.1126/science.282.5393.1494)
20. Price TK, Wolff B, Halverson T, et al. Temporal Dynamics of the Adult Female Lower Urinary Tract Microbiota. 2020. doi: [10.1101/2020.03.06.20032193](https://doi.org/10.1101/2020.03.06.20032193)
22. Gu W, Miller S, Chiu C. Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection. *Annual Review of Pathology: Mechanisms of Disease*. 2019;14(1):319-338. doi: [10.1146/annurev-pathmechdis-012418-012751](https://doi.org/10.1146/annurev-pathmechdis-012418-012751)
23. Hilton SK, Castro-Nallar E, Pérez-Losada M, et al. Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology. *Frontiers in Microbiology*. 2016;7. doi: [10.3389/fmicb.2016.00484](https://doi.org/10.3389/fmicb.2016.00484)
25. Thomas-White KJ, Gao X, Lin H, et al. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. *International Urogynecology Journal*. 2018;29(12):1797-1805. doi: [10.1007/s00192-018-3767-3](https://doi.org/10.1007/s00192-018-3767-3)
26. Barraud O, Ravry C, François B, Daix T, Ploy M-C, Vignon P. Shotgun metagenomics for microbiome and resistome detection in septic patients with urinary tract infection. *International Journal of Antimicrobial Agents*. 2019;54(6):803-808. doi: [10.1016/j.ijantimicag.2019.09.009](https://doi.org/10.1016/j.ijantimicag.2019.09.009)
27. Warren JW, Horne LM, Hebel JR, Marvel RP, Keay SK, Chai TC. Pilot Study Of Sequential Oral Antibiotics For The Treatment Of Interstitial Cystitis. *Journal of Urology*. 2000;163(6):1685-1688. doi: [10.1016/s0022-5347\(05\)67520-9](https://doi.org/10.1016/s0022-5347(05)67520-9)
28. Sharma D, Misba L, Khan A. Antibiotics versus biofilm: an emerging battleground in microbial communities. *Antimicrobial Resistance & Infection Control*. 2019;8(1). doi: [10.1186/s13756-019-0533-3](https://doi.org/10.1186/s13756-019-0533-3)
29. Brubaker L, Carberry C, Nardos R, Carter-Brooks C, Lowder J. American Urogynecologic Society Best-Practice Statement. *Female Pelvic Med Reconstr Surg*. 2018;24(5):321-335. doi: [10.1097/spv.0000000000000550](https://doi.org/10.1097/spv.0000000000000550)
30. Anderson G, Palermo J, Schilling J, Roth R, Heuser J, Hultgren S. Intracellular Bacterial Biofilm-Like Pods in Urinary Tract Infections. *Science* (1979). 2003;301(5629):105-107. doi: [10.1126/science.1084550](https://doi.org/10.1126/science.1084550)
31. Singh R, Sahore S, Kaur P, Rani A, Ray P. Penetration barrier contributes to bacterial biofilm-associated resistance against only select antibiotics, and exhibits genus-, strain- and antibiotic-specific differences. *Pathogens and Disease*. 2016;74(6). doi: [10.1093/femspd/ftw056](https://doi.org/10.1093/femspd/ftw056)
32. Katongole P, Nalubega F, Florence N, Asimwe B, Andia I. Biofilm formation, antimicrobial susceptibility and virulence genes of Uropathogenic Escherichia coli isolated from clinical isolates in Uganda. *BMC Infect Dis*. 2020;20(1). doi: [10.1186/s12879-020-05186-1](https://doi.org/10.1186/s12879-020-05186-1)
33. Lerminiaux N, Cameron A. Horizontal transfer of antibiotic resistance genes in clinical environments. *Can J Microbiol*. 2019;65(1):34-44. doi: [10.1139/cjm-2018-0275](https://doi.org/10.1139/cjm-2018-0275)

[10.1101/2020.03.06.20032193](https://doi.org/10.1101/2020.03.06.20032193)